Medicines Formulary

Medicines A–Z

R

Drug name	NICE TAs	Comments
Revaxis		Supported with PGD
Ribociclib (Kisqali®)	TA496 - Ribociclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer TA593 - Ribociclib with fulvestrant for treating hormone receptor-positive, HER2-negative, advanced breast cancer TA687 - Ribociclib with fulvestrant for treating hormone receptor-positive, HER2-negative, advanced breast cancer	For hospital use only
Riboflavin		Specialist recommendation - inherited metabolic disease.
Rifampicin
Rigevidon		Umbrella service only
Riluzole tablets	TA20 - Guidance on the use of Riluzone (Rilutek) for the treatment of Motor Neurone Disease	ESCA
Rimegepant	TA906 - Rimegepant for preventing migraine TA919 - Rimegepant for treating migraine
Ringer's solution for injection
Risankivzub (Skyrizi®)	TA596 - Risankizumab for treating moderate to severe plaque psoriasis
Risdiplam (Evrysdi®)	TA755 - Risdiplam for treating spinal muscular atrophy

Drug status key

Formulary drugs are allocated a traffic light status. This provides guidance on where clinical and prescribing responsibilities lie in regard to the initiation and maintenance of prescribing.

Grey

Positive NICE TA and/or awaiting local clarification on place in therapy. Please contact your medicines optimisation team for more information.

Red

Initiation and maintenance of prescribing by specialists only.

Amber

Initiation and maintenance of prescribing by specialists and transfer to primary care prescribing when appropriate, or in primary care following a specialists recommendation. Prior to initiation some medicines may require committee agreement or a framework to support safe transfer and maintenance.

Green

Initiation and maintenance of prescribing by specialists, GPs and other qualified clinicians.

Blue

Under review at University Hospitals Birmingham NHS Foundation Trust.